Program
verducatib
Also written as “BI 1291583”, “Verducatib” and “BI 1291583 mixed with [C-14] BI 1291583”.
In Boehringer Ingelheim's pipeline, DPP1/CatC inhibitor
. Its studies are mostly in Bronchiectasis · Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 217 open or running | phase 3since Mar 7, 2025 | Jan 22, 2018 | Dec 14, 2026phase 1 · NCT07781631 |
- Named in Boehringer Ingelheim’s own pipeline as
Verducatib (BI 1291583)
, phase 3, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jan 22, 2018.
- Dec 22, 2021Phase 1 study in HealthyNCT05183347 · 36 enrolled · Japan
- Feb 3, 2022Phase 2 study in BronchiectasisNCT05238675 · 322 enrolled · United States, Australia, Belgium and more
- Apr 17, 2023Phase 1 study in HealthyNCT05833035 · 8 enrolled · Netherlands
- Apr 26, 2023Phase 2 study in BronchiectasisNCT05846230 · 268 enrolled · United States, Australia, Belgium and more
- May 10, 2023Phase 2 study in Cystic FibrosisNCT05865886 · 22 enrolled · United States, Belgium, France and more
- Dec 4, 2023Phase 1 study in HealthyNCT06166992 · 14 enrolled · Netherlands
- Oct 7, 2024Phase 1 study in HealthyNCT06631417 · 30 enrolled · Germany
- Jan 20, 2025Phase 1 study in HealthyNCT06791187 · 14 enrolled · Germany
- Mar 7, 2025Phase 3 study in BronchiectasisNCT06872892 · 1,755 planned · United States, Argentina, Australia and more
- Apr 7, 2025Phase 1 study in HealthyNCT06917872 · 20 enrolled · Germany
- Jun 10, 2025Phase 1 study in HealthyNCT07023354 · 32 planned · United States
- Apr 9, 2026Phase 1 study in HealthyNCT07531628 · 12 enrolled · China
- Aug 7, 20262 phase 1 studies in HealthyNCT07760246, NCT07781631
- Oct 23, 20262 phase 3 studiesNCT07907991, NCT07915219
Ahead
- Dec 14, 2026Primary completion: phase 1 study in HealthyNCT07781631
- Dec 23, 2026Primary completion: phase 1 study in HealthyNCT07023354
- Dec 30, 2026Primary completion: phase 1 study in HealthyNCT07760246
- Mar 31, 2027Primary completion: phase 2 study in BronchiectasisNCT05846230
TargetBeta
“DPP1/CatC inhibitor”the company's pipeline, read by Claude · source
Other programs on CTSC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brensocatibrule | Insmed | phase 3 | 17 |
| RSS0343 | Jiangsu HengRui Medicine | phase 2 | 4 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07915219Bronchiectasis · United States, Argentina, Austria and more | 3 | Not yet recruiting | Jul 31, 2029 | 1,500 |
| NCT07907991Pulmonary Disease, Chronic Obstructive · United States, Italy, Malaysia | 3 | Not yet recruiting | Nov 12, 2029 | 1,800 |
| NCT07781631Healthy · Germany | 1 | Recruiting | Dec 14, 2026 | 20 |
| NCT07760246Healthy · Germany | 1 | Active, not recruiting | Dec 30, 2026 | 56 |
| NCT07531628Healthy · China | 1 | Completed | Jul 14, 2026 | 12 |
| NCT07023354Healthy · United States | 1 | Recruiting | Dec 23, 2026 | 32 |
| NCT06917872Healthy · Germany | 1 | Completed | Sep 9, 2025 | 20 |
| NCT06872892Bronchiectasis · United States, Argentina, Australia and more | 3 | Recruiting | Jun 15, 2027 | 1,755 |
| NCT06791187Healthy · Germany | 1 | Completed | Feb 21, 2025 | 14 |
| NCT06631417Healthy · Germany | 1 | Completed | Jan 10, 2025 | 30 |
| NCT06166992Healthy · Netherlands | 1 | Completed | Feb 7, 2024 | 14 |
| NCT05865886Cystic Fibrosis · United States, Belgium, France and more | 2 | Completed | Oct 7, 2024 | 22 |
| NCT05846230Bronchiectasis · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 31, 2027 | 268 |
| NCT05833035Healthy · Netherlands | 1 | Completed | Jul 5, 2023 | 8 |
| NCT05238675Bronchiectasis · United States, Australia, Belgium and more | 2 | Completed | May 1, 2024 | 322 |
| NCT05183347Healthy · Japan | 1 | Completed | Jul 27, 2022 | 36 |
| NCT04866160Healthy · Germany | 1 | Completed | Nov 30, 2021 | 24 |
| NCT03890887Healthy · Germany | 1 | Completed | Jul 29, 2019 | 14 |
| NCT03868540Healthy · Germany | 1 | Terminated | Nov 25, 2019 | 24 |
| NCT03837964Healthy · Germany | 1 | Completed | Apr 24, 2019 | 12 |
| NCT03414008Healthy · Germany | 1 | Terminated | Nov 18, 2019 | 54 |
How it is read
Names in the registry
- “BI 1291583”, 17 entries
- “Verducatib”, 4 entries
- “verducatib”, 1 entry
- “BI 1291583 mixed with [C-14] BI 1291583”, 1 entry
Conditions, from the studies’ own filings
- Bronchiectasis, 4 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
- Cystic Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.